Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico (original) (raw)
A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Nonabsorbable Antibiotic, in the Treatment of Tropical Enteropathy
Ken Maleta
American Journal of Gastroenterology, 2009
View PDFchevron_right
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
Herbert DuPont
Current Opinion in Gastroenterology, 2010
View PDFchevron_right
The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance
Stacy Weitsman
Digestive Diseases and Sciences, 2013
View PDFchevron_right
In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth
Irene Galani
View PDFchevron_right
Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders
Herbert DuPont
Clinical Infectious Diseases, 2006
View PDFchevron_right
Rifamycin SV-MMX® for treatment of travellers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria
Herbert DuPont
Journal of Travel Medicine, 2018
View PDFchevron_right
Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea: REVIEW: RIFAXIMIN IN TRAVELLERS’ Diarrhoea
Viola Andresen
Alimentary Pharmacology Therapeutics, 2010
View PDFchevron_right
Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates
Joaquim Ruiz
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013
View PDFchevron_right
Rifaximin: beyond the traditional antibiotic activity
solomon tadesse
View PDFchevron_right
Prevention of Travelers' Diarrhea With Rifaximin in US Travelers to Mexico
Norma Hernandez
Journal of Travel Medicine, 2010
View PDFchevron_right
A Randomized, Double-Blind, Multicenter Study of Rifaximin Compared with Placebo and with Ciprofloxacin in the Treatment of Travelers’ Diarrhea
Herbert DuPont
The American Journal of Tropical Medicine and Hygiene, 2006
View PDFchevron_right
Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis
Pablo Bellot
Gut, 2015
View PDFchevron_right
Therapy of travelers’ diarrhea with rifaximin on various continents
Mike Whiting
American Journal of Gastroenterology, 2003
View PDFchevron_right
Rifaximin Treatment of Pathogen‐Negative Travelers’ Diarrhea: Table 1
Herbert DuPont
Journal of Travel Medicine, 2007
View PDFchevron_right
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy
Rosa Infante
Clinical Gastroenterology and Hepatology, 2004
View PDFchevron_right
Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea
Viola Andresen
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease Activity
Ira Shafran
Digestive Diseases and Sciences, 2010
View PDFchevron_right
In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents
Chia-jui Yang
International Journal of Antimicrobial Agents, 2011
View PDFchevron_right
Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth
manuela distefano
Alimentary Pharmacology & Therapeutics, 2000
View PDFchevron_right
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth
Giovanni Cammarota
Alimentary Pharmacology and Therapeutics, 2005
View PDFchevron_right
Targeting of Rifamycin SV to the Colon for Treatment of Travelers' Diarrhea: A Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Study
Jose Flores
Journal of Travel Medicine, 2014
View PDFchevron_right
Empirical Treatment of Severe Acute Community-Acquired Gastroenteritis with Ciproftoxacin
Matthew Dryden
Clinical Infectious Diseases, 1996
View PDFchevron_right
933 Small Intestinal Bacterial Overgrowth Recurrence After Rifaximin Therapy
maria novie
Gastroenterology, 2008
View PDFchevron_right
Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007
Samuel Bouchillon
Diagnostic Microbiology and Infectious Disease, 2010
View PDFchevron_right
In Vitro Antimicrobial Susceptibility of Bacterial Enteropathogens Isolated from International Travelers to Mexico, Guatemala, and India from 2006 to 2008
Herbert DuPont
Antimicrobial Agents and Chemotherapy, 2010
View PDFchevron_right
Rifaximin, a Peculiar Rifamycin Derivative: Established and Potential Clinical Use Outside the Gastrointestinal Tract
Carmelo Scarpignato
Chemotherapy, 2005
View PDFchevron_right
Rifaximin for the prevention of spontaneous bacterial peritonitis
Athanasia Mouzaki
2012
View PDFchevron_right
Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology
Maria Tomas
Enfermedades Infecciosas y Microbiología Clínica, 2015
View PDFchevron_right
Role of antimicrobials in the treatment of adult patients presenting to the emergency department with acute gastroenteritis - A mini review
Abbas M . Malik
Pakistan journal of medical sciences
View PDFchevron_right
Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
Jose cruz dominguez Martinez
Enfermedades Infecciosas y Microbiología Clínica, 2015
View PDFchevron_right
Bile Acids Improve the Antimicrobial Effect of Rifaximin
Charles Darkoh
Antimicrobial Agents and Chemotherapy, 2010
View PDFchevron_right
A Randomized, Double‐Blind, Pilot Study of Rifaximin 550 mg Versus Placebo in the Prevention of Travelers' Diarrhea in Mexico During the Dry Season: Table 1
Mercedes Paredes
Journal of Travel Medicine, 2011
View PDFchevron_right
Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints
Ching-lin Shyu
The Journal of Infection in Developing Countries, 2014
View PDFchevron_right